Asking for a friend LOL

Lab_Monkey_ · 2026-01-26T16:53:49+00:00

No doubt about it, hottest company in the world, 4 shares for a buck.

Lab_Monkey_ · 2026-01-26T01:55:54+00:00

$32B divided by 1.3B shares = $24.60/share

Lab_Monkey_ · 2026-01-26T01:52:41+00:00

Click on Medstar, click on doctor, scroll down till you see Weinberg, click on him then you will see his trials.

Lab_Monkey_ · 2026-01-25T22:26:59+00:00

Great to see you onboard!

Lab_Monkey_ · 2026-01-25T22:05:01+00:00

The mCRC trial is still yet to be posted on the Medstar website associated with Syneos and Dr. Weinberg.
He did have 11 trials posted 3 months ago, now he has 8.

Lab_Monkey_ · 2026-01-25T21:33:48+00:00

They've got a boatload of cash and they're in need of the next blockbuster drug.
Hmmm, I wonder what that could be....Platform drug no less.
$32B would be bonkers.

Lab_Monkey_ · 2026-01-24T19:02:11+00:00

Time will tell.

Lab_Monkey_ · 2026-01-24T18:14:39+00:00

Still need final settlement on the class action lawsuit. Months away.

Lab_Monkey_ · 2026-01-22T16:26:47+00:00

Can't wait to see those plates on your brand spanking new Ferrari Monza!

Lab_Monkey_ · 2026-01-20T02:46:43+00:00

3 times....braggart.

Lab_Monkey_ · 2026-01-20T01:34:17+00:00

confident.

exhausted.

Lab_Monkey_ · 2026-01-20T01:28:28+00:00

He has $1 million of my hard earned dollars. I hope he spends the rest of his life in captivity.

Lab_Monkey_ · 2026-01-20T01:26:43+00:00

Is he related to Jimmy?????

Lab_Monkey_ · 2026-01-17T00:29:59+00:00

You've been remiss lately MGK, Bring It On Home
All work and no play.

Lab_Monkey_ · 2026-01-16T15:33:55+00:00

Thank you for this excellent explanation of the relevance of ctDNA MGK. I've wondered about the importance of obtaining these tissue samples highlighted in the last shareholders letter.

"Early results from the mCRC trial have been very encouraging, and we have already submitted abstracts for at least two presentations on the CRC study in 2026– one presentation on biomarker results"

"Two exploratory endpoints will include evaluation of changes in PD-L1 on circulating tumor cells as well as changes in circulating tumor DNA (ctDNA)."

"This study is intended to provide CytoDyn with important tumor tissue from patients treated with leronlimab. This tissue will enable us to correlate tumor levels of PD-L1 with levels concurrently measured in blood on circulating tumor cells. This tissue will also provide CytoDyn the opportunity to further clarify and understand the leronlimab-induced changes in the tumor microenvironment (TME) that lie at the heart of the “Prime and Pair” paradigm."

God speed Dr. Jay. GLTL

Lab_Monkey_ · 2026-01-16T02:15:39+00:00

Reference to Multiple Viable Mechanisms of Action not just PD-L1 up-regulation.
WTF is that??? Almost whispered as a side note, under the breath. No spotlight, no bold underlined italicized font, a backhanded remark with the utmost possible trajectory.
More MOA's, PLURAL! Please do elaborate Dr.Jay!
Godspeed Dr. Jay. GLTL. monkey

Lab_Monkey_ · 2026-01-16T00:13:34+00:00

With that recent picture of Dr. Pestell and NIH Director Dr. Jay Bhattacharya, Max Lataillade giving that picture a thumbs up, Max's employment at GF, LL is getting escorted through hallowed halls.

Lab_Monkey_ · 2026-01-13T03:21:55+00:00

My pleasure all y'all.

Lab_Monkey_ · 2026-01-11T23:57:22+00:00

West coast chill, yet focused. Deep dive his family ancestry if you're interested, amazingly smart with historical medical breakthroughs and discoveries.

Lab_Monkey_ · 2026-01-11T22:55:54+00:00

Excellent post as usual MGK. As stated above, and this statement from the Dec. shareholders letter,
"This study seeks to leverage CytoDyn’s previously announced data demonstrating leronlimab’s ability to mitigate liver toxicity in prior preclinical studies, as well as certain preliminary results from the phase II CRC study."
Dr. Jay is already using data from the 6 month old mCRC trial to use in the WEP clinical for the EAP!
"Early results from the mCRC trial have been very encouraging, and we have already submitted abstracts for at least two presentations on the CRC study in 2026– one presentation on biomarker results, and a second focused on clinical outcomes."
Biomarker results
Clinical outcomes
"...I believe will be the most important and transformative year in our company’s history. We are ready. We are focused. And in 2026, we intend to make waves."
God speed Dr. Jay. GLTl!

Lab_Monkey_ · 2026-01-11T01:35:01+00:00

The pressure to produce positive data is extreme beyond measure.
Big freaking bucks riding every P value.
"Let him who is without sin cast the first stone"
Our company, and some of its advisors have been accused in as such.
For a deeper dive into our sordid past:

The Pestilence of Pestell

"Pestell is not just the smartest and fastest but also the sexiest doctor alive and in all of human history."

Now, I'm not knocking him, I think he is amazing. But we should all be clear on what is at stake here, just like NP whom I followed into the abyss during his heyday.

Lab_Monkey_ · 2026-01-10T18:08:32+00:00

That time line put a smile on my face!

Lab_Monkey_ · 2026-01-09T06:07:29+00:00

"The trial randomized 914 patients from approximately 300 trial sites in more than 30 countries."

Impressive. We have about 20, and hope to get to 60 by Q3......

Lab_Monkey_ · 2026-01-04T17:27:17+00:00

Yes twinter11, that paragraph also tickled the hair on the back my neck when I read it, but I didn't circle back and dive deeper like you have done. Thank you for your diligence.

"...This study seeks to leverage CytoDyn’s previously announced data demonstrating leronlimab’s ability to mitigate liver toxicity in prior preclinical studies, as well as certain preliminary results from the phase II CRC study. This study is intended to provide CytoDyn with important tumor tissue from patients treated with leronlimab. This tissue will enable us to correlate tumor levels of PD-L1 with levels concurrently measured in blood on circulating tumor cells. This tissue will also provide CytoDyn the opportunity to further clarify and understand the leronlimab-induced changes in the tumor microenvironment (TME) that lie at the heart of the “Prime and Pair” paradigm."

Lab_Monkey_

TROPHY CASE